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At a Glance 
T he U.S. Centers for Disease Control and Prevention (CDC), Division of Tuberculosis Elimination (DTBE), International Research and Programs Branch (IRPB) has worked closely with Ministries of Health (MOH) for more than 30 years, strengthening capacity to 
prevent and control diseases and reducing health risk behaviors. IRPB’s work globally focuses on 
infection control, multidrug-resistant (MDR) TB, general TB control program strengthening, and 
identifying, treating and preventing TB among people living with HIV (PLHIV). Together with 
partners, IRPB supports programs that develop and strengthen local skills and public health 
systems in areas including epidemiology, laboratory, and management science. 
This report summarizes many of IRPB’s accomplishments over the past year, highlighting both 
internal cross-program synergies and external partnerships. IRPB’s Atlanta, Georgia, office has 
over 30 multidisciplinary staff.   IRPB and locally employed staff work together in Botswana, 
Cambodia, China, India, Thailand, and Vietnam. 
Let s eliminate TB. (Photo Credit: Brittany Moore, CDC) 
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uberculosis (TB) is one of the world’s deadliest diseases.  Approximately 
one-third of the world’s population is infected with Mycobacterium tuberculosis. 
Each year, globally, more than 9 million people become sick with TB disease and 
almost 2 million will die from TB. TB is also the leading cause of death among 
people living with HIV, undermining global progress against both diseases. 
IRPB In-country Presence and Ongoing Extensive Collaborations 
T
IRPB’s mission is to reduce TB prevalence and 
mortality globally, as well as among foreign-
born persons in the United States. Activities 
are carried out through collaborations within 
CDC, the U.S. Agency for International 
Development (USAID), other U.S. government 
(USG) agencies, the World Health Organization 
(WHO), Ministries of Health (MOH), and 
other international partners. 
 
IRPB is comprised of more than 30 employees  
with diverse backgrounds in administration, 
architecture, behavioral science, clinical 
medicine, engineering, epidemiology, genetics, 
infection control, microbiology, pediatrics, 
research, and statistics.  IRPB also has a 
significant and growing international presence, 
with field staff located in Botswana, China, 
India, and Thailand. IRPB has additional 
ongoing collaborations with governments and 
research institutions in Cambodia, Kenya, 
Mexico, Russia, South Africa, and Vietnam, as 
shown on the map. 
IRPB’s priority areas include: supporting TB 
control efforts worldwide through program 
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strengthening and epidemiologic studies; 
improving infection control (IC) practices to 
prevent TB transmission and provide a safer 
environment in health facilities and other 
congregate settings; improving and expanding 
the diagnosis, treatment, and prevention of 
drug-resistant (DR) TB; and reducing TB/HIV 
prevalence and mortality through epidemiologic 
research and technical assistance.  
Partners 
IRPB collaborates with many external partners. 
USAID primarily funds the technical assistance 
IRPB provides internationally.  Other partners 
include: 
•	USG agencies (e.g., Office of the U.S. Global 
AIDS Coordinator [OGAC], National 
Institute of Allergy and Infectious Diseases/ 
National Institutes of Health [NIAID/ 
NIH], Fogarty International Center/National 
Institutes of Health [FIC/NIH], and the 
Department of Defense [DoD]); 
•	country governments (e.g., Botswana MOH, 
Government of India, and the Royal Thai 
Government); 
•	multilateral organizations (e.g., WHO, 
Global Fund, World Bank); 
•	donors (e.g., KNCV Tuberculosis 
Foundation [KNCV], Research Institute 
Tuberculosis, Japan Anti-Tuberculosis 
Association [RIT, JATA], Bill and Melinda 
Gates Foundation); 
•	non-governmental organizations (e.g., 
International Union Against Tuberculosis 
and Lung Disease [IUATLD], Treatment 
Action Group, U.S. Civilian Research and 
Development Foundation, Project Hope); 
•	universities and schools of public health; and 
•	other key institutions. 
Partner signage . (Photo credits: Gloria Oramasionwu, CDC and Alex Miranda, UNAIDS) 
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IRPB Organizational Structure and Highlights   
IRPB is composed of four teams: TB Infection Control, Drug-Resistant (DR) TB, Program 
Strengthening and Epidemiology, and TB/HIV. The teams collaborate with other USG agencies 
and partners to address the needs of in-country USG offices and MOH.  This work is accomplished by 
providing technical expertise, assisting in research design and oversight, developing and implementing 
trainings, and supporting programmatic implementation of innovative approaches to TB control.  
Additionally, IRPB has field staff in Botswana, China, India, Thailand, and Washington, DC.  
DTBE- International Research and Programs Branch 
Organizational Chart (2010) 
IRPB
 Eugene McCray, Chief 
Bryan Kim, Senior PHA 




























Teams and Field Assignees 
Staff Transition 
In 2010, IRPB welcomed Drs. Gloria 
Oramasionwu and Lindsay Kim, Epidemic 
Intelligence Service (EIS) Officers to 
support epidemiologic research and program 
evaluation of international TB programs. 
Garry Blackwelder, an architect, joined the TB 
Infection Control Team to lead TB IC trainings 
and provide technical assistance on optimal 
design and renovation of facilities for quality 
TB infection control.  Rosanna Boyd joined 
CDC-Botswana to provide program, research, 
and technical assistance support to the Botswana 
MOH and other in-country partners.  
Graduating EIS Officer Dr. Sean Cavanaugh 
joined the Drug-Resistant (DR) TB Team as a 
Medical Officer.  Graduating EIS Officer Dr. 
Philip Ricks left IRPB to join the Surveillance 
Branch in the Division of Healthcare Quality 
Promotion (DHQP), CDC as a Senior Service 
Fellow. Dr. Taraz Samandari, former Associate 
Director of TB/HIV Research Division in 
Botswana is now Chief of the Epidemiology 




TB Infection (IC) Control Team 
Team Overview 
In resource-limited settings, the risk of TB 

transmission in health care and congregate 

facilities can be effectively reduced with 

practical precautions and administrative 

interventions.  The TB IC Team develops, 

informs, and improves international 

guidance on TB IC practices to prevent 

TB transmission, trains TB IC specialists 

to oversee implementation, designs TB IC 

monitoring and evaluation metrics, and 





Health care workers receive training in testing 
respirators for proper fit and use . (Photo credit: Grigory 
V . Volchenkov, Vladimir Oblast TB Dispensary) 
Select Accomplishments 
•	Developed TB training modules which are 
posted on the Stop TB Partnership Web site 
at www.stoptb.org/wg/tb_hiv/icshome.asp. 
•	In 2002, a comprehensive TB IC 
program was started at the Vladimir 
Oblast Tuberculosis Dispensary. Formal 
establishment of a center occurred in 
October 2008 with the opening of the 
Vladimir Center of Excellence (CoE) for 
Tuberculosis Infection Control.  The Center 
is a partnership with the Vladimir Oblast 
Administration, USAID, CDC/DTBE, 
Central Tuberculosis Research Institute 
(CTRI –Moscow), and WHO –Moscow. The 
CoE serves as an IC training hub for Russia 
and other Commonwealth of Independent 
States (CIS). The TB IC Team provides 
instruction, monitoring, and implementation 
of administrative, environmental, and 
personal protective TB controls.  As a result, 
there has been a remarkable reduction in 
occupationally-acquired TB in the Vladmir 
Oblast TB Dispensary; down from 1083 to 
166 new cases per 100,000, with no new TB 
cases reported in 2010. 
Future Projects 
•	Collaborate with Division of Global HIV/ 
AIDS Program to develop a Biological 
Safety Cabinet (BSC) certification school in 
Africa to address a severe lack of qualified 
technicians who are trained in appropriate 
use of safety cabinets and ventilated work 
stations. This lack of trained personnel has 
resulted in a higher risk for contracting TB 
for local health care workers who are required 
to perform lab procedures that should 
be performed under a BSC or ventilated 
workstation. 
•	Develop guidelines for laboratory biosafety, 
and assist the Vladimir CoE for TB IC 
in establishing a TB laboratory biosafety 
training course in Russia. 
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Drug-Resistant (DR) TB Team 
Team Overview 
The pandemic of MDR TB has underscored 
the need for higher quality services in 
traditional TB control, as well as greater 
investments in rapid diagnosis and treatment 
of TB that does not respond to first-line 
TB drugs.  The DR TB Team works with 
Ministries of Health (MOH), WHO, local 
and international NGOs, USG agencies, 
U.S. state health departments, and others 
to improve and expand diagnosis, proper 
treatment, and prevention of drug-resistant 
TB. These efforts are focused internationally, 
as well as domestically among foreign-
born persons in the United States, through 
provision of technical assistance, trainings, 
and conducting research and demonstration 
projects of innovative approaches. 
Select Accomplishments 
•	 In collaboration with the MOH and local 
partners in nine countries, the DR TB Team 
spearheaded the Preserving Effective TB 
Treatment Study (PETTS).  PETTS has 
informed the new framework for WHO and 
international partners in providing universal 
access to diagnosis, treatment, and care of 
MDR TB.  PETTS, a large multi-year, multi-
country study compared programs approved 
by the Green Light Committee (GLC) to 
programs that were not GLC approved to 
determine the incidence and consequences 
of acquired resistance to second-line drugs 
(SLD) among MDR TB patients.  GLC is a 
mechanism that enables access to affordable, 
high-quality, second-line anti-TB drugs for 
the treatment of MDR TB. Preliminary 
results suggest that acquired resistance to 
these drugs was lower in GLC approved 
programs.  GLC approved programs also 
demonstrated higher cure rates, lower 
mortality, and lower treatment failure rates 
when compared with non-GLC approved 
programs.  
PETTS site: a laboratory in the Vladimir Oblast TB 
Dispensary in Russia .  (Photo credit: Ekaterina Kurbatova, 
CDC) 
•	Evaluated optimal strategies for the 

microbiological monitoring of the 

effectiveness of MDR TB treatment.  This 

was done using retrospective case-based data 

on cohorts of MDR TB patients treated 

with SLD at the first five Directly Observed 

Treatment/Therapy Short Course (DOTS)­
Plus pilot projects approved by the GLC 






•	Implement and evaluate novel technologies 

for rapid diagnosis of anti-TB drug 

resistance. Collect credible evidence to 

guide scale-up of strategies to optimize 

case detection and the diagnosis of drug 





•	Develop and test strategies to improve 

treatment of DR TB, and develop analytic 

methods to model the effectiveness of 

various therapeutic approaches to DR TB.
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Program Strengthening and 
Epidemiology (PSE) Team 
Team Overview 
The Program Strengthening and 
Epidemiology (PSE) Team has a broad 
portfolio of projects aimed at supporting 
TB control efforts worldwide, as well 
as among foreign-born populations 
in the United States.  The PSE team 
supports programs in resource-limited 
international settings by conducting 
research on the epidemiology of TB 
and by providing technical assistance 
in development, implementation, and 
assessment of surveillance and program 
evaluation policies.  The team also designs 
and conducts demonstration projects of 
established TB control measures and rapid 
diagnostics in resource-limited settings to 
assess their impact and determine optimal 
approaches for implementation.  In the 
United States, the team supports and 
provides assistance to programs aimed 
at reducing the incidence of TB among 
foreign-born persons prior to their arrival 
in the country. 
Research nurse educating clients on TB in Botswana . 
(Photo credit: Joe Lockridge, Peace Corps) 
Select Accomplishments 
•	Conducted operational research trainings in 
the Philippines and India, resulting in the 
design of 26 studies by training graduates.  
•	Collaborated with the Research Institute 
Tuberculosis, Japan Anti-Tuberculosis 
Association (RIT, JATA) to teach 
“Fundamentals of Epidemiology and TB 
Operations Research,” as part of the 3-month 
International Stop TB Action Training.  At 
the end of the project, each participant 
developed a protocol for an operational 
research project in his respective country. 
•	Collaborated with the WHO Global Task 
Force on TB Impact Measurement to 
publish the second edition of “Tuberculosis 
Prevalence Surveys:  A Handbook.” 
Future Projects 
•	Implement and evaluate the integration of 
rapid diagnostics for TB and MDR TB into 
routine TB programs in resource-limited 
countries. 
•	Support the development of standards and 
benchmarks for TB surveillance in low and 
middle income countries in collaboration 





HIV/AIDS has led to increasing TB 
incidence and mortality, particularly in 
high HIV-burden countries.  Globally, 
TB is the leading cause of death for 
people living with HIV (PLHIV).  
HIV-associated TB (TB/HIV) threatens 
to undermine progress made in TB and 
HIV control around the world. The 
TB/HIV Team aims to reduce TB/HIV 
prevalence and mortality in resource-
limited settings by conducting high-
impact research and demonstration 
projects to implement, evaluate, and 
validate innovative TB/HIV control 
approaches; providing technical assistance 
to resource-limited countries to guide 
design and implementation of TB/HIV 
programs; and by informing international 
policy.  Research activities primarily focus 
on intensified TB case finding among 
PLHIV, isoniazid preventive therapy 
(IPT) among PLHIV, and pediatric TB/ 
HIV. 
Select Accomplishments 
•	Led a cross-sectional study “Improving 
Diagnosis of TB in HIV-infected Persons:  
The ID-TB/HIV Study” enrolling more 
than 2,000 PLHIV from eight antiretroviral 
(ARV) clinics in Cambodia, Thailand, and 
Vietnam to determine the best method for 
screening and diagnosing TB in PLHIV.  
The study found that using previously 
recommended screening approaches failed to 
detect more than two-thirds of patients with 
TB disease. However, screening PLHIV for 
TB using a combination of three symptoms 
detected almost all cases among this 
population. (Of note, patients with a positive 
symptom screen need liquid culture to most 
accurately diagnose TB disease.)  Further, 
this combination symptom screening method 
Worldwide, TB is one of the leading causes of death 
among people living with HIV . (Photo credit: Alex 
Miranda, UNAIDS) 
reliably ruled-out TB in those patients 
without TB disease, (97% without TB had 
no symptoms), allowing isoniazid preventive 
therapy (IPT) to be started more quickly.  In 
follow up to this study, CDC and WHO 
collaborated on a meta-analysis which led to 
a change in WHO’s international guidelines 
for screening for TB among PLHIV.  
•	Contributed to the development of the 
“U.S. Public Health Guidelines for the 
Prevention and Control of HIV/AIDS, Viral 
Hepatitis, Sexually Transmitted Diseases, and 
Tuberculosis among Persons who Use Illicit 
Drugs in the United States.”  
Future Projects 
•	Validate new intensified TB case finding 
approaches and evaluate the implementation 
of GeneXpert in HIV care settings. 
•	Develop evidence based approaches to 
pediatric TB screening; and improve 
diagnosis and management of TB in 
children, including evaluation of promising 
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Luanda IRPB In-Country Presence 

IRPB has in-country presence in Botswana, China, India, and Southeast Asia.  IRPB provides technical assista ce and resources for the prevention and treatment of TB.  Five DTBE/IRPB direct hire employees and more than 40 locally employed staff and 
contractors are working in National TB Programs, carrying out programmatic TB 
activities, operational research, and capacity building.  The information in this section 
highlights the contributions and planned projects in these select countries. 
Republic of Botswana 
Capital City:  Gaborone 
Area:  582,000 sq . km . (224,710 sq . mi .) 
Population (est.): 1 .86 million  (Source: www .state .gov) 
Estimated TB Incidence/Prevalence, 2009: 
694/100,000; 531/100,000 
(Source: WHO Global TB Control Report 2010) 
Number of people living with HIV at the end 
of 2009: 320,000 
(Source: UNAIDS, Report on the Global AIDS 
Epidemic, 2010) 
Estimated HIV Prevalence, (Age 15-49) 2009: 24 .8% 
(Source: UNAIDS, Report on the Global AIDS 
Epidemic, 2010) 
HIV+ incident TB cases: (% of all TB cases): 66% 
(Source: WHO Global TB Control Report 2010) 
Estimated TB deaths in 2007: 194/100,000 
(Source: WHO Global TB Control Report 2009) 
PEPFAR/GAP Office 
IRPB Presence in Botswana 
Z i m b a b w 





















































Since 1995, CDC Botswana has played an 
important role in extending the reach of 
Botswana’s national TB response, with HIV/ 
AIDS becoming a strong f cus in 2000. 
CDC Botswana was initially established as 
a partnership with the Botswana MOH to 
strengthen TB control through public health 
research; it has evolved over the years to focus 
primarily on stopping the spread of TB and 
HIV/AIDS in southern Africa. CDC Botswana 
conducts training, technical assistance, and 
research; promotes innovation and evidence-
based best practices; and supports the monitoring 
and evaluation of prevention, care, and treatment 
programs for HIV/AIDS and TB. 
Select Accomplishments 
•	Isoniazid Prevention Therapy Trial (IPTT): The 
IPTT, conducted from 2004 to 2011, was 
designed to determine whether 36 months 
of isoniazid treatment was more effective in 
preventing TB disease among PLHIV than the 
routinely prescribed six month treatment.  The 
main finding was that while IPT was highly 
effective (>90% reduction) in reducing TB in 
people with a positive tuberculin skin test, 36 
months of IPT was much more effective than 
the current standard of providing six months 
of IPT for these persons. CDC Botswana has 
worked closely with the Botswana National 
TB and HIV Programs, including providing 
cost effectiveness analysis to modify the 
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[2 DTBE/IRPB CDC Direct Hire employees (named  below), 28 Locally Employed Staff ] 












Structure of TB/HIV Research Division in Botswana 
National IPT Program based on the IPTT 
findings. The trial continues to monitor 
incident TB in those who received IPT.  
WHO used these study findings to update 
its policy.  This study informed a change in 
WHO recommendations, now suggesting 
that PLHIV with a positive TB skin test 
should receive 36 months of IPT. 
•	Clinical trial/treatment: CDC Botswana 
is conducting the first clinical trial of TB 
treatment in Botswana.  The RIFAQUIN 
Trial is a multi-country clinical trial, 
coordinated by St. George’s Hospital and 
the Medical Research Council of the United 
Kingdom, examining the efficacy of high-
dose short-course rifapentine coupled with 
moxifloxacin for the treatment of drug-
sensitive TB.  A study team in Francistown, 
Botswana began enrolling patients in 
October 2010.  As a part of this study, CDC 
Botswana will increase the capacity of the 
National Tuberculosis Reference Laboratory 
by enhancing their capabilities to support 
second-line drug susceptibility testing.  As 
a result of preparation for this trial, a new 
facility in Francistown is now fully equipped 
for future clinical trials. 
Future Plans 
•	Enhance clinical trial capability for Botswana 
by strengthening the National TB Reference 
Laboratory’s capacity to perform culture, 
line-probe assays, and second-line drug 
sensitivity testing. 
•	Strengthen country capacity to detect new 
TB cases in PLHIV through infrastructure 
developed for implementation of the Early 
Mortality Reduction Group (EMRG) Study. 
EMERG evaluates the extent of lives saved 
due to enhanced TB case finding at ART 
clinics. 
Lab technician at CDC Botswana performing IGRA assay . 
(Photo credit: Sean Toney, CDC) 
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The People’s Republic of China 
Capital City:  Beijing 
Area:  9,600,000 sq . km . (3,706,580 sq . mi .) 
Population (est.): 1,353,311,000
(Source: www .state .gov) 
Estimated TB Incidence/Prevalence, 2009: 
Estimated HIV Prevalence (Age 15-49), 2009: 
0 .1% (Source: UNAIDS, Report on the Global AIDS 
Epidemic, 2010) 
HIV+ incident TB cases (% of all TB cases): 4% 
(Source: WHO Global TB Control Report 2010 
96/100,000; 138/100,000
(Source: WHO Global TB Control Report 2010)
 
Number of people living with HIV at the end of 
2009: 740,000 
(Source: UNAIDS, Report on the Global AIDS 
Epidemic, 2010) 
Estimated TB deaths in 2009: 15/100,000
(Source: WHO Global TB Control Report 2010) 
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U.S. CDC has provided technical assistance to 
China’s TB control efforts through the Division 
of Global HIV/AIDS Program and DTBE for 
the past 10 years. In 2008, U.S. CDC’s newly 
created Global Disease Detection (GDD) 
Program in China began focusing on TB. In 
2009, DTBE/IRPB began providing 50% 
support for an epidemiologist within GDD. 
DTBE/IRPB’s activities, conducted through 
GDD, are centered on technical support and 
training to advance control of drug-resistant 
tuberculosis. 
Select Accomplishments 
•	IC Policy and training to reduce transmission 
of TB and MDR TB:  During large, acute 
outbreaks of respiratory infections such 
as SARS and pandemic H1N1 influenza, 
China demonstrated a tremendous ability 
to strengthen IC in health care facilities. 
In routine practice, however, China has 
no national policy for how to reduce 
transmission of TB in health care facilities. 
Generally, practices do not adhere to 
international recommendations for TB IC. 
In 2010, CDC assisted the National TB 
Program in developing the first national 
government publication about TB IC 
in health care facilities. The “China TB 
Infection Control Handbook” was written by 
Chinese experts in consultation with CDC 
and WHO.  The handbook is now being 
distributed throughout the country.  With 
sponsorship by WHO, China’s National TB 
program also held a large training course on 
TB IC in August 2010. DTBE/IRPB staff 
served as trainers for respiratory infection 
control and assessments of health care facility 
ventilation. 
•	Assessments of TB transmission in health 
care facilities:  Although transmission of TB 
and MDR TB in health care facilities is an 
important global public health problem, 
few studies in China have systematically 
evaluated the prevalence of TB infection and 
disease in health care workers, identified risk 
factors for infection, or studied health care 
worker knowledge, attitudes, and practices. 
In 2010, DTBE/IRPB collaborated with the 
National TB Program to complete a survey of 
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4,200 healthcare workers in Inner Mongolia 
province. To reliably measure TB infection 
rates, CDC microbiologists installed 
equipment, provided supplies, and conducted 
training for performing the QuantiFERON-
TB Gold In-Tube test (QFT) at two hospitals 
in Inner Mongolia. Preliminary findings from 
this survey include: (a) the prevalence of TB 
infection in health care workers, as assessed 
by QFT, was over 60%; (b) increased risk 
of TB infection was associated with hospital 
exposures, not community exposures; and 
(c) baseline TB infection control knowledge 
levels were generally high, but some 
false beliefs existed about ways to reduce 
transmission. 
Future Plans 
•	Continue to work with CDC China and 
the MOH to advance TB IC in health care 
facilities. Activities will include assistance 
with development, implementation, and 
monitoring of standard operating procedures 
for health care facilities; epidemiologic 
studies to evaluate the risk of health care 
worker TB infection and strategies to reduce 
risk; and technical support to partners (e.g., 
WHO, Gates Foundation, Global Fund) to 
support training of health care workers and 
assessment of health care facility practices. 
•	Work with China CDC to implement a 
multi-country study evaluating the rate of 
TB infection in households with MDR TB 
patients. 
Nurses in Hohhot, China, evaluating blood volume in tubes . The blood will be analyzed using QuantiFERON-TB Gold 

















Republic of India 
Capital City:  New Delhi 
Area:  3 .29 million sq . km . (1 .27 million sq . mi .) 
Population (est.): 1 .17 billion; urban 29% 
(Source: www .state .gov) 
Estimated TB Incidence/Prevalence, 2009: 
168/100,000; 249/100,000 
(Source: WHO Global TB Control Report 2010; 
incidence and prevalence provisional WHO 
estimates and not agreed to by GoI, and expected 
to be revised in 2011 following WHO-GoI 
consultation) 
Number of people living with HIV at the end 
of 2009: 2,400,000 
(Source: UNAIDS, Report on the Global AIDS 
Epidemic, 2010) 
Estimated HIV Prevalence (Age 15-49), 2009: 
0 .3% 
(Source: UNAIDS, Report on the Global AIDS 
Epidemic, 2010) 
HIV+ Incident TB cases, 2009: 12% 
Estimated TB deaths in 2009: 28/100,000 
(Source: WHO Global Report, 2010) 
IRPB Presence in India 
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DTBE/IRPB has provided technical assistance 
for TB control efforts in India in collaboration 
with USAID, the Southeast Asia Regional Office 
(SEARO) of the World Health Organization 
(WHO), and the Government of India, 
Revised National Tuberculosis Control Program 
(RNTCP).  Since 1997, DTBE/IRPB has 
maintained an assigned medical officer position 
in India.  The DTBE/IRPB assignee is detailed 
to WHO/SEARO and provides technical 
support to the RNTCP. DTBE/IRPB is focused 
on providing comprehensive technical support 
for strengthening TB control, with emphasis on: 
1. development and expansion of TB/HIV 
services and TB infection control activities in 
India; 
2. expansion of the programmatic management 
of MDR TB activities within RNTCP; and 




Full DOTS expansion efforts began in 1998, 
with full nationwide coverage achieved in 2006. 
Since 2006, national efforts have been directed 
to strengthen implementation of DOTS, along 
with all aspects of the Stop TB Partnership’s 
comprehensive Global Strategy. 
Select Accomplishments: 
•	MDR TB and TB laboratory scale-up: DTBE/ 
IRPB and partners developed national scale up 
plans, and facilitated the adoption by RNTCP 
of a new diagnostic algorithm for MDR TB.  
The new algorithm is based on rapid diagnosis 
using molecular rapid diagnostics. DTBE/ 
IRPB and partners secured, committed third 
party financing for accelerated laboratory and 
treatment service expansion. 
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•	TB IC: DTBE/IRPB and partners organized 
a national steering body for IC, developed 
the first national guidelines on airborne 
infection control, created a standard training 
and education curriculum, and developed 
capacity at national and state levels for pilot 
testing the national guidelines. Data from 
the pilot test will be used for policy revision. 
Future Plans 
•	Contribute to the process of developing 
the next National Strategic Plan to Control 
TB 2012 – 2017. Upon implementation, 
this plan is expected to dramatically expand 
government expenditure on TB control and 
support with implementation. 
•	Support large scale pilot testing of new 
diagnostics, including GeneXpert MTB/RIF, 
in public and private settings. 
MDR TB patient in Ahmedabad, shortly after hospitalization and shortly before death . In Gujarat, 
40% of MDR TB patients have fluoroquinolone resistance (also known as pre-XDR TB) . (Photo 
credit: Puneet Dewan, CDC, detailed to WHO/SEARO) 
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DTBE/IRPB has worked with the Thai 
Ministry of Public Health (MOPH) 
and the CDC Southeast Asia Regional 
Office since 2003 to develop initiatives 
and research that lead to effective TB 
control policies.  DTBE/IRPB has a 
Regional TB Technical Advisor (Medical 
Officer) stationed in Bangkok.  Program 
staff also provides technical assistance t  
other countries in the region, including 
Cambodia, Laos, and Vietnam, and to 
the WHO regional offices in New Delhi 
and Manila.  Strategies used to reduce the 
burden of TB in Thailand and Southeast 
Asia include developing epidemiologic 
models, measuring incidence and mortality, 
and promoting best practices.  The program 
collaborates closely with the Royal Thai 
Government, other USG partners, and 
multilateral, national, and NGO partners 
to conduct research, inform policy, support 
program implementation, and build 
program capacity. 
Structure of TB Program in Thailand 
3 Lab Coordinators 
Director 
Sara Whitehead, MD 
1 Epidemiologist 1 Programmer 2 Project Coordinators 
Program Management Assistant Secretary 
[1 CDC Direct Hire employee (named  below), 9 Locally Employed Staff ] 
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Selected Accomplishments: 
•	Intensified TB case finding for people 
with HIV:  DTBE, with USAID support, 
completed a large multi-country study in 
Thailand, Cambodia, and Vietnam called 
“Improving Diagnosis of TB in HIV-Infected 
Persons:  The ID-TB/HIV Study.”  This 
multi-center, cross-sectional study enrolled 
over 2,000 HIV-infected patients to 
determine the optimal algorithm to screen 
and diagnose TB in PLHIV.  The study 
found that a combination of three symptoms 
is an effective tool for screening PLHIV for 
TB, sufficient to reliably rule out TB in most 
patients who have none of these symptoms 
(screen negative).  Most of the remaining 
patients who have any of these symptoms 
need liquid culture to reliably diagnose TB.  
In follow up to this study, DTBE and WHO 
collaborated on a meta-analysis which led to 
a change in WHO’s international guidelines 
for screening for TB among persons with 
HIV.  CDC also worked with partners at the 
Thai Healthcare Intervention and Technology 
Assessment Program (HITAP) to determine 
the cost-effectiveness of the newly defined TB 
screening algorithm for people with HIV. 
•	TB screening in people with acute pneumonia: 
The regional TB program collaborated with 
DTBE and IEIP/GDD colleagues to conduct 
enhanced surveillance for TB among people 
with acute pneumonia in two sites for 
population-based surveillance of respiratory 
disease. DTBE initiated the project, 
developed lab procedures, and analyzed and 
interpreted the data. This work helps identify 
people with TB who would otherwise be 
missed, thus preventing treatment delays 
and further transmission of TB within 
health care facilities.  Further investigation is 
underway to determine which patients with 
TB are being missed, with an aim to develop 
guidance on how to improve TB case finding 
in this population. 
Future Plans 
•	Pilot and evaluate programmatic 
implementation of new evidence-based 
approaches to TB screening and isoniazid 
preventive therapy in Cambodia, Thailand, 
and Vietnam. The findings on barriers and 
feasibility will be used to assist countries with 
scale up planning. 
•	TB IC is a new area of focus in Southeast 
Asia. Although the need to prevent TB 
transmission in health care facilities is widely 
recognized, the efficacy of IC interventions 
is not well documented; policy makers have 
little information available to make decisions 
about where to target resources.  Projects 
in Thailand and Vietnam have assessed the 
current status of infection control practices 
in health care facilities and LTBI rates among 
health care staff.  Planning is underway for a 
large trial, including 16 hospitals in Thailand 
and Vietnam, to evaluate the impact of a 
package of IC support measures on both 
LTBI in health care staff, and on staff 
carrying out recommended infection control 
procedures.  
•	Support and evaluate the implementation 
of new rapid diagnostic tests such as the 
GeneXpert MTB/RIF test in a variety of 
settings. 
Hmong Refugees providing sputum samples in Thailand 
(Photo credit: Sean Toney, CDC) 
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Hmong Refugees providing sputum samples in Thailand 
(Photo credit: Sean Toney, CDC)
2010 Articles Published in 
Peer-Reviewed Journals 
In addition to conducting epidemiologic research, providing technical assistance, and supporting 
program implementation, translating research into practice is a major priority for IRPB.  Disseminating 
findings to local and international partners, as well as the broader TB and TB/HIV communities, is a 
critical component of the majority of IRPB projects.  In collaboration with USG and CDC partners, 
MOH, and partner NGOs, IRPB staff has made significant contributions to the literature.  Below is a 
list of IRPB publications for 2010, listed alphabetically by first author.  
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19 
Dewan PK, Gupta D, Williams BG, Thakur R, Bachani D, Khera A, Wares DF, Sahu S, Reddy DCS, Raizada 
N Chauhan LS. National estimate of HIV seroprevalence among tuberculosis patients in India.  [Short 
communication] Int J Tuberc Lung Dis 2010 Feb; 14(2):247-9 . 
Kane S, Dewan PK, Gupta D, Wi T, Das A, Singh A, Bitra G, Chauhan LS, Dallabetta G. Large-scale public-
private partnership for improving TB-HIV services for high-risk groups in India. [Notes from the Field.] Int J 
Tuberc Lung Dis 2010 Aug; 14(8):1066–1068 . 
Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, Skenders G, Holtz TH. Treatment 
outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 
584–593. 
Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence 
and body mass index. Int J Epidemiology 2010 Feb; 39(1): 149-155. 
Menzies HJ, Winston CA, Holtz TH, Cain KP, Mac Kenzie WR. Epidemiology of tuberculosis among US- 
and foreign-born children and adolescents in the United States, 1994–2007. Am J Public Health 2010 Sep; 
100(9):1724-9. Also Epub 2010 Jul 15. 
Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew T, Tedla Z, Motsamai O, Kilmarx PH, Wells 
CD, Samandari T. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral 
therapy: a Botswana experience, 2004-2006. JAIDS 2010 May 1; 54(1): 71-77. 
Nabbuye-Sekandi J, Okot-Chono R, Rusen ID, Dlodlo RA, Katamba A, Tumwesigye NM, Fujiwara PI. Factors 
associated with human immunodeficiency virus testing among tuberculosis patients receiving treatment at health 
facilities in Uganda. Int J Tuberc Lung Dis 2010 July; 14(7): 896-902. 
Ohkado A, Pevzner E, Sugiyama T, Murakami K, Yamada N, Cavanaugh S, Ishikawa N, Harries AD. 
Evaluation of an international training course to build programmatic capacity for tuberculosis control. [Short 
communication.] Int J Tuberc Lung Dis 2010 March; 14(3): 371-373. 
Pevzner ES, Robison S, Donovan J, Allis D, Spitters C, Friedman R, Ijaz K, Oeltmann JE. Tuberculosis 
transmission and use of methamphetamines in Snohomish County, WA, 1991-2006. Am J Public Health 2010 
Dec;100(12):2481-6. Also Epub 2010 Feb 18. 
Podewils LJ, Holtz T, Riekstina V, Skripconoka V, Zarovska E, Kirvelaite G, Kreigere E, Leimane V. Impact of 
malnutrition on clinical presentation, clinical course, and mortality in MDR TB patients. Epidemiol Infect 2010 
Apr 30:1-8. 
Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, et al. Costs and consequences of additional chest x-ray in a 
tuberculosis prevention program in Botswana. Am J Respir Crit Care Med 2010 Dec 10. [Epub ahead of print.] 
Sculier D, Vannarith C, Pe R, Thai S, Kanara N, Borann S, Cain KP, Lynen L, Varma JK. Performance of 
abdominal ultrasound for diagnosis of tuberculosis in HIV-infected persons living in Cambodia. J Acquir Immune 
Defic Syndr. 2010;55:500-2. 
Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, Vernon A, Wells CD, and Samandari T. 
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-infected adults in 
Botswana. Am J Respir Crit Care Med 2010; 182: 278-285. 
Varma JK, McCarthy KD, Tasaneeyapan T, Monkongdee P, Kimerling M, Buntheon E, Sculier D, Keo C, 
Phanuphak P, Teeratakulpisarn N, Udomsantisuk N, Dung NH, Lan NTN, Yen NTB, Cain KP. Bloodstream 
infections among HIV-infected outpatients, Southeast Asia. Emerg Infect Dis 2010;16:1569-1575. 
Wongsrichanalai C, Varma JK, Juliano JJ, Kimerling ME, MacArthur JR. Extensive drug resistance in malaria and 




ART Antiretroviral Therapy/Treatment 
ARV Antiretroviral 
BSC Biological Safety Cabinet 
CoE Center of Excellence 
CIS Commonwealth of Independent States 
DOTS Directly Observed Treatment/ 
Therapy Short Course 
DGHA Division of Global HIV/AIDS Program, 
CDC 
DGMQ Division of Global Migration and 
Quarantine, CDC 
DHQP Division of Healthcare Quality Promotion,  
CDC 
DHAP Division of HIV/AIDS Prevention, CDC 
DTBE Division of Tuberculosis Elimination, CDC 
DRS Drug Resistance Survey 
DR TB Drug Resistant TB 
DST Drug Sensitivity Testing 
EMERG Early Mortality Reduction Group 
EIS Epidemic Intelligence Service 
EMB, E Ethambutol 
GDD Global Disease Detection 
GLC Green Light Committee 
HITAP Healthcare Intervention and Technology 
Assessment Program 
HIV/AIDS Human Immunodeficiency Virus/ 
Acquired Immune Deficiency Syndrome 
IC Infection Control 
ICF Intensified Case Finding 
IEIP International Emerging Infections 
Program 
IRPB International Research and Programs 
Branch, DTBE, CDC 
IUATLD International Union Against TB and 
Lung Disease (The “Union”) 
H Isoniazid 
IPT Isoniazid Preventive Therapy 
IPTT Isoniazid Preventive Therapy Trial 
KNCV KNCV Tuberculosis Foundation 
M & E Monitoring and Evaluation 
MDR TB Multidrug-Resistant TB 
MOH Ministry of Health 
MSF Medicines Sans Frontiers (Doctors 
without Borders) 
MSH Management Sciences for Health 
NRL National Reference Laboratory 
NGO Non-governmental organization 
OD Office of the Director 
OGAC Office of Global AIDS Coordination 
OI Opportunistic Infection 
OR Operations Research 
PHA Public Health Advisor 
PLHIV People Living with HIV 
PEPFAR President’s Emergency Plan for 
AIDS Relief 
PETTS Preserving Effective TB Treatment Study 
(multinational) 
PMTCT Preventive Maternal to Child Transmission 
(HIV) 
PSE Program Strengthening and 
Epidemiology 
PZA Pyrazinamide 
QFT GIT QuantiFERON-TB Gold In-Tube 
RIF, R Rifampin 
RIT, JATA The Research Institute Tuberculosis,  
Japan Anti-Tuberculosis Association 
SEARO South East Asia Regional Office 
SLD Second-Line Drugs 
S, SM, STM Streptomycin 
TA Technical Assistance 
TB Tuberculosis 
TB/HIV Tuberculosis/ Human 
Immunodeficiency Virus 
TST Tuberculin Skin Test 
USAID U.S. Agency for International 
Development 
USG United States Government 
WHO World Health Organization 
XDR TB Extensively Drug Resistant TB 
International Research and Programs Branch 
Annual Report 
2010 
U.S. Centers for Disease Control and Prevention 
Office of Infectious Diseases 
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Division of Tuberculosis Elimination 
International Research and Programs Branch 
1600 Clifton Road, MS-E10 
Atlanta, Georgia 30333 
CS225756 
